Current and Emerging Bispecifics in Multiple Myeloma: Clinical Data Review

home / training-academy / current-and-emerging-bispecifics-in-multiple-myeloma-clinical-data-review

A panel of experts on multiple myeloma review recent clinical trial data and discuss the evolving treatment landscape, focusing on the role of bispecific therapy.

A panel of 4 experts on multiple myeloma

EP. 1: Significance of GPRC5D as a Target for R/R MM

Ajai Chari, MD;Noopur Raje, MD;Rafael Fonseca, MD;Larysa Sanchez, MD

September 6th 2024

A panel of experts on multiple myeloma discuss the importance of GPRC5D as a target of interest in relapsed/refractory disease and discuss their experiences with talquetamab in clinical practice.

EP. 2: Long-Term Follow-Up of MonumenTAL-1

Ajai Chari, MD;Noopur Raje, MD;Rafael Fonseca, MD;Larysa Sanchez, MD

September 6th 2024

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

EP. 3: MonumenTAL-1: Efficacy and Safety Data

Ajai Chari, MD;Noopur Raje, MD;Rafael Fonseca, MD;Larysa Sanchez, MD

September 13th 2024

Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.

EP. 4: Broader Implications and Current Trials of GPRC5D-Targeted Treatments in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD;Noopur Raje, MD;Rafael Fonseca, MD;Larysa Sanchez, MD

September 13th 2024

Hematologist-oncologists discuss GPRC5D-targeting treatments that are currently in development for patients with relapsed/refractory multiple myeloma.